Journal Obliges Authors and Yank Ketamine Study medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.
Relmada Therapeutics Announces Poster Presentations at the American Psychiatric Association Annual Meeting 2021
News provided by
Share this article
Share this article
NEW YORK, May 1, 2021 /PRNewswire/ Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that clinical data related to REL-1017, the company s lead product candidate, will be presented in two posters at the American Psychiatric Association (APA) Annual Meeting 2021, which is being held virtually between May 1 and May 3, 2021.
Details of the poster presentations are below:
Date/Time:
Poster Number: 5181
Title: Rapid and Sustained Antidepressant Effects of REL-1017 (esmethadone) as an Adjunctive Treatment for Major Depressive Disorder: A Phase 2 Trial